PAR paradigm biopharmaceuticals limited..

Sharewise Presentation 22/7/24, page-117

  1. 6,677 Posts.
    lightbulb Created with Sketch. 1306
    In the interview Paul says we were monitoring the 600 patients in the dose escalation study for retinal damage due to elmiron's retinal damage assertions... no evidence at all of any damage in our 600 patients according to Paul.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
42.0¢
Change
0.000(0.00%)
Mkt cap ! $166.9M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 2380 42.0¢
 

Sellers (Offers)

Price($) Vol. No.
41.0¢ 2391 2
View Market Depth
Last trade - 09.02am 21/07/2025 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.